Vertex announces positive day 90 data for the first patient in the phase 1/2 clinical trial dosed with vx-880, a novel investigational stem cell-derived therapy for the treatment of type 1 diabetes

Boston--(business wire)--vertex today announced positive data for the first patient from the phase 1/2 clinical trial of vx-880, for the treatment of type-1 diabetes.

VRTX Ratings Summary

VRTX Quant Ranking